Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein

Subbiah Pugazhenthi, Albina Nesterova, Carol L. Sable et al. · Journal of Biological Chemistry · 2000 · 801 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +15

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

James C. Cusack, Rong Liu, Michael E. Houston et al. · PubMed · 2001 · 548 citations

Medicine, Oncology, Pharmacology +16

Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer

Sergio Catz, Jennifer L. Johnson · Oncogene · 2001 · 526 citations

Medicine, Molecular Biology, Oncology +16

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

John B. Sunwoo, Zhong Chen, Guo‐Chung Dong et al. · PubMed · 2001 · 479 citations

Medicine, Molecular Biology, Oncology +16